Pharmerging Market to Grow At 13% CAGR To 2020

Pharmerging Markets 2016-2020 report says, increase in public and private healthcare insurance is the primary growth driver for this market.

December 1, 2015 /MarketersMedia/ —

The research analyst predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The pharmerging markets are highly fragmented due to the presence of numerous small and large vendors. Most of the international pharmaceutical companies are facing challenges such as price pressure, regulatory constraints, and competition from local and other international pharmaceutical companies in the pharmerging markets. The competitive environment in the market is expected to intensify with an increase in product extensions, technological innovations, and increase in mergers and acquisitions.

The Complete Report Pharmerging Markets 2016-2020 104 pages research is available at http://www.reportsnreports.com/reports/444861-pharmerging-markets-2016-2020.html.

The following companies are the key players in the Pharmerging Market: AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer and Sanofi

Other Prominent Vendors in the market are: Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical, UCB, and Valeant Pharmaceuticals.

The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs.

Segmentation and analysis of the pharmerging markets
Tier I countries (China)
Tier II countries (Brazil, India, and Russia)
Tier III countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)

The Tier I region (China) dominated the market during 2015, with a market share of 45%. An ageing population, increase in healthcare spending, and rise in market opportunities in suburban and rural areas are the main factors fueling the growth of the market in China. Order a Single User License Copy of Pharmerging Markets 2016-2020 Report at http://www.reportsnreports.com/Purchase.aspx?name=444861.html for US $3000.

Commenting on the Pharmerging Market report, an analyst said: Pharmerging countries mostly include developing or less-developed countries where the affordability of drugs plays a major role for the blossoming of the market. Hence, the utilization and sale of generic drugs are high. Though the sales of generics have slowed down, the sales still outpace the sales of originator molecules. Also, pharmaceutical companies such as Pfizer and Sanofi are showing an interest toward the development of generics for attaining considerable shares in the pharmerging markets.

According to the Pharmerging Market report, public and private healthcare insurance are among the major drivers influencing the growth of this market. The governments of pharmerging countries such as India have implemented schemes that can be availed by eligible patients to obtain free treatment for diseases.

Table of Contents

PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Global pharmaceuticals market
Market size and forecast
PART 06: Pharmerging markets
PART 07: Market landscape
Market size and forecast
Five forces analysis
PART 08: Market segmentation based on geography
PART 09: Market overview of Tier I countries
China
PART 10: Market overview of Tier II countries
Brazil
Russia
India
PART 11: Market overview of Tier III countries
Market size and forecast
PART 12: Market drivers
Social and private health insurance
Increase in healthcare spending
High incidence of diseases
Impact of patent cliff on mature markets
PART 13: Impact of drivers
PART 14: Market challenges
Affordability and access
High competition
Partial regulatory policies
Price pressure
PART 15: Impact of drivers and challenges
PART 16: Market trends
Strategic alliances
Increase in generic sales
Mergers and acquisitions
Early drug launches in pharmerging markets
PART 17: Vendor landscape
Competitive scenario
AstraZeneca
GlaxoSmithKline
Merck
Novartis
Pfizer
Sanofi
Other prominent vendors
PART 18: Appendix
List of abbreviations

For more information inquire @ http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=444861

About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

For more information about us, please visit http://www.reportsnreports.com/reports/444861-pharmerging-markets-2016-2020.html

Contact Info:
Name: Ritesh Tiwari
Organization: ReportsnReports
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar, Pune, Maharashtra 411013, India.
Phone: + 1 888 391 5441

Source: http://marketersmedia.com/pharmerging-market-to-grow-at-13-cagr-to-2020/98002

Release ID: 98002